Business
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.
About this update from Sophia Genetics Sa
[{"type":"text","content":"BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.","length":514,"tagName":"p"},{"type":"image","alt":"SOPHiA GENETICS Logo","displaySize":"","headline":null,"caption":"SOPHiA GENETICS Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n6kFaeXBXi.jQBj8QTEY9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b","width":400,"height":267}}},{"type":"text","content":""When we announced one million profiles analyzed in 2022, it was a landmark moment in the evolution of data-driven medicine," said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS. "Less than three years later, we have doubled that number, an acceleration that reflects both the trust our partners place in our Platform and the increasing role of AI in transforming healthcare."","length":429,"tagName":"p"},{"type":"text","content":"With 800 healthcare institutions across 72 countries regularly contributing their data and expertise to SOPHiA DDM™, the Platform has become one of the most comprehensive sources of real-world intelligence in precision medicine. SOPHiA DDM™ analyzes thousands of new oncology and rare disease cases daily, continuously refining and improving its AI capabilities. Unlike AI models trained in controlled environments, SOPHiA GENETICS's technology is uniquely shaped by real-world data, ensuring its insights are deeply rooted in clinical reality. Now informed by over two million patient cases, the Platform empowers providers to see what others cannot, leading to faster and more accurate treatment decisions.","length":717,"tagName":"p"},{"type":"text","content":""At SOPHiA GENETICS, our...